Investor Relations

Overview

Zogenix, Inc. (Nasdaq: ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
NASDAQ | ZGNX (Common Stock)
$11.000.00
Stock chart for: ZGNX.O.  Currently trading at $11.00 with a 52 week high of $13.70 and a 52 week low of $7.33.
Data as of 04/28/17 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.

Latest Presentations

Zogenix April 2017 Investor Presentation
Download Documentation

Recent News More

Zogenix Completes Enrollment in First ZX008 Phase 3 Clinical Trial in Dravet Syndrome

Read More

Zogenix to Release First Quarter 2017 Financial Results and Host Conference Call and Webcast on May 4

Read More

Investor Events More

Thursday, May 4, 2017 4:30 p.m. ET
Q1 2017 Zogenix, Inc. Earnings Conference Call